RADIOTHERAPY AND ONCOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=558351, encodeId=e0ad5583519e, content=距5分就差一丢丢.不知最终版可否超越5分...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Tue Jun 26 21:49:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553324, encodeId=5d245533241f, content=Received at Editorial Office: 30-NOV-2017 Article revised: 18-FEB-2018 Article accepted for publication: 26-FEB-2018 Expected dispatch of proofs: 12-MAR-2018188****8186(暂无匿称) 2018-01-22 23:44:00 发表: under review 40天后.Under Editor Evaluation, beContent=188****8186(暂无匿称) 2018-01-22 23:44:00 发表: under review 40天后.Under Editor Evaluation, objectType=tool_impact_factor, channel=null, level=null, likeNumber=249, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553117, encodeId=69cf55311e21, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Nov 30, 2017 提交 Feb 28, 2018Completed - Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Wed Feb 28 20:07:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551849, encodeId=df48551849fd, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：under review 40天后.Under Editor Evaluation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Jan 22 23:44:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551707, encodeId=2ba4551e07ef, content=红皮都过五了，投稿应该越来越难。。。绿皮还在4分几徘徊。。。祈祷它可以过五吧，bless...分数和声誉完全不匹配啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Fri Jan 19 19:26:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549999, encodeId=961f5499994b, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿过3次.前两次都在一周内被拒.这次With editor 13天后Under review.希望能顺利发表., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Thu Dec 14 12:44:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548511, encodeId=91a454851135, content=一篇综述，列出审稿时间，供参考 Initial Date Submitted Aug 29, 2017 Submitted to Journal Aug 29, 2017 With Editor Aug 31, 2017 Under Review Sep 10, 2017 Under Review Sep 12, 2017 Under Editor Evaluation Oct 23, 2017 Decision in Process Oct 23, 2017, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=299, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a22794, createdName=119254319, createdTime=Tue Oct 24 09:06:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544079, encodeId=8d245440e9d4, content=徘徊不前,不过处于这个关口上的期刊,再往上冲已不易了,4分多,也算满意了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=wang_di98, createdTime=Sun Jul 16 19:01:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=537566, encodeId=afef53e566c1, content=什么类型文章？zhu1270 2012-09-04 发表:: 奇怪的很，我投了20天不到就接受了！只是修改语言zhu1270 2012-09-04 16:10:00 发表: 奇怪的很，我投了20天不到就接受了！只是修改语言, beContent=zhu1270 2012-09-04 发表:: 奇怪的很，我投了20天不到就接受了！只是修改语言, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73361629515, createdName=zhangsilin, createdTime=Sat Jun 10 00:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531311, encodeId=8e245313115e, content=一篇前年12月投稿到绿皮的手稿，历经一次中修和一次小修，最后接收并于去年年中发表。这篇文章最一开始投的是10+的杂志，经众一区杂志秒拒的洗礼，最后被绿皮接收，也算是一个不错的结果。谢谢编辑和审稿人的认可，尤其其中一位认为我们的工作是极具开创性的（a rather interesting new direction of thought in the field）。希望在放射肿瘤学的主流杂志上（红皮和绿皮，当然更高级的CR等）有更多国人的声音,也希望所在的研究组在以后的日子里会有更多的工作在红皮、绿皮等权威杂志上发表。祝大家好运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=285, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Mon Jan 02 10:17:00 CST 2017, time=2017-01-02, status=1, ipAttribution=)]

2018-06-26 @MD & PhD@

距5分就差一丢丢.不知最终版可否超越5分....

200 0

[GetPortalCommentsPageByObjectIdResponse(id=558351, encodeId=e0ad5583519e, content=距5分就差一丢丢.不知最终版可否超越5分...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Tue Jun 26 21:49:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553324, encodeId=5d245533241f, content=Received at Editorial Office: 30-NOV-2017 Article revised: 18-FEB-2018 Article accepted for publication: 26-FEB-2018 Expected dispatch of proofs: 12-MAR-2018188****8186(暂无匿称) 2018-01-22 23:44:00 发表: under review 40天后.Under Editor Evaluation, beContent=188****8186(暂无匿称) 2018-01-22 23:44:00 发表: under review 40天后.Under Editor Evaluation, objectType=tool_impact_factor, channel=null, level=null, likeNumber=249, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553117, encodeId=69cf55311e21, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Nov 30, 2017 提交 Feb 28, 2018Completed - Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Wed Feb 28 20:07:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551849, encodeId=df48551849fd, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：under review 40天后.Under Editor Evaluation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Jan 22 23:44:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551707, encodeId=2ba4551e07ef, content=红皮都过五了，投稿应该越来越难。。。绿皮还在4分几徘徊。。。祈祷它可以过五吧，bless...分数和声誉完全不匹配啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Fri Jan 19 19:26:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549999, encodeId=961f5499994b, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿过3次.前两次都在一周内被拒.这次With editor 13天后Under review.希望能顺利发表., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Thu Dec 14 12:44:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548511, encodeId=91a454851135, content=一篇综述，列出审稿时间，供参考 Initial Date Submitted Aug 29, 2017 Submitted to Journal Aug 29, 2017 With Editor Aug 31, 2017 Under Review Sep 10, 2017 Under Review Sep 12, 2017 Under Editor Evaluation Oct 23, 2017 Decision in Process Oct 23, 2017, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=299, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a22794, createdName=119254319, createdTime=Tue Oct 24 09:06:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544079, encodeId=8d245440e9d4, content=徘徊不前,不过处于这个关口上的期刊,再往上冲已不易了,4分多,也算满意了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=wang_di98, createdTime=Sun Jul 16 19:01:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=537566, encodeId=afef53e566c1, content=什么类型文章？zhu1270 2012-09-04 发表:: 奇怪的很，我投了20天不到就接受了！只是修改语言zhu1270 2012-09-04 16:10:00 发表: 奇怪的很，我投了20天不到就接受了！只是修改语言, beContent=zhu1270 2012-09-04 发表:: 奇怪的很，我投了20天不到就接受了！只是修改语言, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73361629515, createdName=zhangsilin, createdTime=Sat Jun 10 00:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531311, encodeId=8e245313115e, content=一篇前年12月投稿到绿皮的手稿，历经一次中修和一次小修，最后接收并于去年年中发表。这篇文章最一开始投的是10+的杂志，经众一区杂志秒拒的洗礼，最后被绿皮接收，也算是一个不错的结果。谢谢编辑和审稿人的认可，尤其其中一位认为我们的工作是极具开创性的（a rather interesting new direction of thought in the field）。希望在放射肿瘤学的主流杂志上（红皮和绿皮，当然更高级的CR等）有更多国人的声音,也希望所在的研究组在以后的日子里会有更多的工作在红皮、绿皮等权威杂志上发表。祝大家好运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=285, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Mon Jan 02 10:17:00 CST 2017, time=2017-01-02, status=1, ipAttribution=)]

2018-03-06 1dd96cb3m86(暂无匿称)

Received at Editorial Office: 30-NOV-2017 Article revised: 18-FEB-2018 Article accepted for publication: 26-FEB-2018 Expected dispatch of proofs: 12-MAR-2018188****8186(暂无匿称) 2018-01-22 23:44:00 发表:
under review 40天后.Under Editor Evaluation

188****8186(暂无匿称) 2018-01-22 23:44:00 发表: under review 40天后.Under Editor Evaluation

249 0

[GetPortalCommentsPageByObjectIdResponse(id=558351, encodeId=e0ad5583519e, content=距5分就差一丢丢.不知最终版可否超越5分...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Tue Jun 26 21:49:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553324, encodeId=5d245533241f, content=Received at Editorial Office: 30-NOV-2017 Article revised: 18-FEB-2018 Article accepted for publication: 26-FEB-2018 Expected dispatch of proofs: 12-MAR-2018188****8186(暂无匿称) 2018-01-22 23:44:00 发表: under review 40天后.Under Editor Evaluation, beContent=188****8186(暂无匿称) 2018-01-22 23:44:00 发表: under review 40天后.Under Editor Evaluation, objectType=tool_impact_factor, channel=null, level=null, likeNumber=249, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553117, encodeId=69cf55311e21, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Nov 30, 2017 提交 Feb 28, 2018Completed - Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Wed Feb 28 20:07:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551849, encodeId=df48551849fd, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：under review 40天后.Under Editor Evaluation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Jan 22 23:44:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551707, encodeId=2ba4551e07ef, content=红皮都过五了，投稿应该越来越难。。。绿皮还在4分几徘徊。。。祈祷它可以过五吧，bless...分数和声誉完全不匹配啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Fri Jan 19 19:26:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549999, encodeId=961f5499994b, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿过3次.前两次都在一周内被拒.这次With editor 13天后Under review.希望能顺利发表., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Thu Dec 14 12:44:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548511, encodeId=91a454851135, content=一篇综述，列出审稿时间，供参考 Initial Date Submitted Aug 29, 2017 Submitted to Journal Aug 29, 2017 With Editor Aug 31, 2017 Under Review Sep 10, 2017 Under Review Sep 12, 2017 Under Editor Evaluation Oct 23, 2017 Decision in Process Oct 23, 2017, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=299, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a22794, createdName=119254319, createdTime=Tue Oct 24 09:06:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544079, encodeId=8d245440e9d4, content=徘徊不前,不过处于这个关口上的期刊,再往上冲已不易了,4分多,也算满意了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=wang_di98, createdTime=Sun Jul 16 19:01:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=537566, encodeId=afef53e566c1, content=什么类型文章？zhu1270 2012-09-04 发表:: 奇怪的很，我投了20天不到就接受了！只是修改语言zhu1270 2012-09-04 16:10:00 发表: 奇怪的很，我投了20天不到就接受了！只是修改语言, beContent=zhu1270 2012-09-04 发表:: 奇怪的很，我投了20天不到就接受了！只是修改语言, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73361629515, createdName=zhangsilin, createdTime=Sat Jun 10 00:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531311, encodeId=8e245313115e, content=一篇前年12月投稿到绿皮的手稿，历经一次中修和一次小修，最后接收并于去年年中发表。这篇文章最一开始投的是10+的杂志，经众一区杂志秒拒的洗礼，最后被绿皮接收，也算是一个不错的结果。谢谢编辑和审稿人的认可，尤其其中一位认为我们的工作是极具开创性的（a rather interesting new direction of thought in the field）。希望在放射肿瘤学的主流杂志上（红皮和绿皮，当然更高级的CR等）有更多国人的声音,也希望所在的研究组在以后的日子里会有更多的工作在红皮、绿皮等权威杂志上发表。祝大家好运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=285, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Mon Jan 02 10:17:00 CST 2017, time=2017-01-02, status=1, ipAttribution=)]

2018-02-28 1dd96cb3m86(暂无匿称)

审稿速度:2.0 | 投稿命中率:25.0
经验分享：Nov 30, 2017 提交 Feb 28, 2018Completed - Accept

208 0

[GetPortalCommentsPageByObjectIdResponse(id=558351, encodeId=e0ad5583519e, content=距5分就差一丢丢.不知最终版可否超越5分...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Tue Jun 26 21:49:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553324, encodeId=5d245533241f, content=Received at Editorial Office: 30-NOV-2017 Article revised: 18-FEB-2018 Article accepted for publication: 26-FEB-2018 Expected dispatch of proofs: 12-MAR-2018188****8186(暂无匿称) 2018-01-22 23:44:00 发表: under review 40天后.Under Editor Evaluation, beContent=188****8186(暂无匿称) 2018-01-22 23:44:00 发表: under review 40天后.Under Editor Evaluation, objectType=tool_impact_factor, channel=null, level=null, likeNumber=249, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553117, encodeId=69cf55311e21, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Nov 30, 2017 提交 Feb 28, 2018Completed - Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Wed Feb 28 20:07:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551849, encodeId=df48551849fd, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：under review 40天后.Under Editor Evaluation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Jan 22 23:44:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551707, encodeId=2ba4551e07ef, content=红皮都过五了，投稿应该越来越难。。。绿皮还在4分几徘徊。。。祈祷它可以过五吧，bless...分数和声誉完全不匹配啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Fri Jan 19 19:26:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549999, encodeId=961f5499994b, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿过3次.前两次都在一周内被拒.这次With editor 13天后Under review.希望能顺利发表., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Thu Dec 14 12:44:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548511, encodeId=91a454851135, content=一篇综述，列出审稿时间，供参考 Initial Date Submitted Aug 29, 2017 Submitted to Journal Aug 29, 2017 With Editor Aug 31, 2017 Under Review Sep 10, 2017 Under Review Sep 12, 2017 Under Editor Evaluation Oct 23, 2017 Decision in Process Oct 23, 2017, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=299, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a22794, createdName=119254319, createdTime=Tue Oct 24 09:06:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544079, encodeId=8d245440e9d4, content=徘徊不前,不过处于这个关口上的期刊,再往上冲已不易了,4分多,也算满意了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=wang_di98, createdTime=Sun Jul 16 19:01:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=537566, encodeId=afef53e566c1, content=什么类型文章？zhu1270 2012-09-04 发表:: 奇怪的很，我投了20天不到就接受了！只是修改语言zhu1270 2012-09-04 16:10:00 发表: 奇怪的很，我投了20天不到就接受了！只是修改语言, beContent=zhu1270 2012-09-04 发表:: 奇怪的很，我投了20天不到就接受了！只是修改语言, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73361629515, createdName=zhangsilin, createdTime=Sat Jun 10 00:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531311, encodeId=8e245313115e, content=一篇前年12月投稿到绿皮的手稿，历经一次中修和一次小修，最后接收并于去年年中发表。这篇文章最一开始投的是10+的杂志，经众一区杂志秒拒的洗礼，最后被绿皮接收，也算是一个不错的结果。谢谢编辑和审稿人的认可，尤其其中一位认为我们的工作是极具开创性的（a rather interesting new direction of thought in the field）。希望在放射肿瘤学的主流杂志上（红皮和绿皮，当然更高级的CR等）有更多国人的声音,也希望所在的研究组在以后的日子里会有更多的工作在红皮、绿皮等权威杂志上发表。祝大家好运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=285, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Mon Jan 02 10:17:00 CST 2017, time=2017-01-02, status=1, ipAttribution=)]

2018-01-22 1dd96cb3m86(暂无匿称)

审稿速度:2.0 | 投稿命中率:25.0
经验分享：under review 40天后.Under Editor Evaluation

246 0

[GetPortalCommentsPageByObjectIdResponse(id=558351, encodeId=e0ad5583519e, content=距5分就差一丢丢.不知最终版可否超越5分...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Tue Jun 26 21:49:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553324, encodeId=5d245533241f, content=Received at Editorial Office: 30-NOV-2017 Article revised: 18-FEB-2018 Article accepted for publication: 26-FEB-2018 Expected dispatch of proofs: 12-MAR-2018188****8186(暂无匿称) 2018-01-22 23:44:00 发表: under review 40天后.Under Editor Evaluation, beContent=188****8186(暂无匿称) 2018-01-22 23:44:00 发表: under review 40天后.Under Editor Evaluation, objectType=tool_impact_factor, channel=null, level=null, likeNumber=249, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553117, encodeId=69cf55311e21, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Nov 30, 2017 提交 Feb 28, 2018Completed - Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Wed Feb 28 20:07:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551849, encodeId=df48551849fd, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：under review 40天后.Under Editor Evaluation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Jan 22 23:44:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551707, encodeId=2ba4551e07ef, content=红皮都过五了，投稿应该越来越难。。。绿皮还在4分几徘徊。。。祈祷它可以过五吧，bless...分数和声誉完全不匹配啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Fri Jan 19 19:26:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549999, encodeId=961f5499994b, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿过3次.前两次都在一周内被拒.这次With editor 13天后Under review.希望能顺利发表., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Thu Dec 14 12:44:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548511, encodeId=91a454851135, content=一篇综述，列出审稿时间，供参考 Initial Date Submitted Aug 29, 2017 Submitted to Journal Aug 29, 2017 With Editor Aug 31, 2017 Under Review Sep 10, 2017 Under Review Sep 12, 2017 Under Editor Evaluation Oct 23, 2017 Decision in Process Oct 23, 2017, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=299, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a22794, createdName=119254319, createdTime=Tue Oct 24 09:06:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544079, encodeId=8d245440e9d4, content=徘徊不前,不过处于这个关口上的期刊,再往上冲已不易了,4分多,也算满意了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=wang_di98, createdTime=Sun Jul 16 19:01:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=537566, encodeId=afef53e566c1, content=什么类型文章？zhu1270 2012-09-04 发表:: 奇怪的很，我投了20天不到就接受了！只是修改语言zhu1270 2012-09-04 16:10:00 发表: 奇怪的很，我投了20天不到就接受了！只是修改语言, beContent=zhu1270 2012-09-04 发表:: 奇怪的很，我投了20天不到就接受了！只是修改语言, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73361629515, createdName=zhangsilin, createdTime=Sat Jun 10 00:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531311, encodeId=8e245313115e, content=一篇前年12月投稿到绿皮的手稿，历经一次中修和一次小修，最后接收并于去年年中发表。这篇文章最一开始投的是10+的杂志，经众一区杂志秒拒的洗礼，最后被绿皮接收，也算是一个不错的结果。谢谢编辑和审稿人的认可，尤其其中一位认为我们的工作是极具开创性的（a rather interesting new direction of thought in the field）。希望在放射肿瘤学的主流杂志上（红皮和绿皮，当然更高级的CR等）有更多国人的声音,也希望所在的研究组在以后的日子里会有更多的工作在红皮、绿皮等权威杂志上发表。祝大家好运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=285, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Mon Jan 02 10:17:00 CST 2017, time=2017-01-02, status=1, ipAttribution=)]

2018-01-19 @MD & PhD@

红皮都过五了，投稿应该越来越难。。。绿皮还在4分几徘徊。。。祈祷它可以过五吧，bless...分数和声誉完全不匹配啊

207 0

[GetPortalCommentsPageByObjectIdResponse(id=558351, encodeId=e0ad5583519e, content=距5分就差一丢丢.不知最终版可否超越5分...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Tue Jun 26 21:49:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553324, encodeId=5d245533241f, content=Received at Editorial Office: 30-NOV-2017 Article revised: 18-FEB-2018 Article accepted for publication: 26-FEB-2018 Expected dispatch of proofs: 12-MAR-2018188****8186(暂无匿称) 2018-01-22 23:44:00 发表: under review 40天后.Under Editor Evaluation, beContent=188****8186(暂无匿称) 2018-01-22 23:44:00 发表: under review 40天后.Under Editor Evaluation, objectType=tool_impact_factor, channel=null, level=null, likeNumber=249, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553117, encodeId=69cf55311e21, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Nov 30, 2017 提交 Feb 28, 2018Completed - Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Wed Feb 28 20:07:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551849, encodeId=df48551849fd, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：under review 40天后.Under Editor Evaluation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Jan 22 23:44:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551707, encodeId=2ba4551e07ef, content=红皮都过五了，投稿应该越来越难。。。绿皮还在4分几徘徊。。。祈祷它可以过五吧，bless...分数和声誉完全不匹配啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Fri Jan 19 19:26:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549999, encodeId=961f5499994b, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿过3次.前两次都在一周内被拒.这次With editor 13天后Under review.希望能顺利发表., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Thu Dec 14 12:44:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548511, encodeId=91a454851135, content=一篇综述，列出审稿时间，供参考 Initial Date Submitted Aug 29, 2017 Submitted to Journal Aug 29, 2017 With Editor Aug 31, 2017 Under Review Sep 10, 2017 Under Review Sep 12, 2017 Under Editor Evaluation Oct 23, 2017 Decision in Process Oct 23, 2017, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=299, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a22794, createdName=119254319, createdTime=Tue Oct 24 09:06:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544079, encodeId=8d245440e9d4, content=徘徊不前,不过处于这个关口上的期刊,再往上冲已不易了,4分多,也算满意了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=wang_di98, createdTime=Sun Jul 16 19:01:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=537566, encodeId=afef53e566c1, content=什么类型文章？zhu1270 2012-09-04 发表:: 奇怪的很，我投了20天不到就接受了！只是修改语言zhu1270 2012-09-04 16:10:00 发表: 奇怪的很，我投了20天不到就接受了！只是修改语言, beContent=zhu1270 2012-09-04 发表:: 奇怪的很，我投了20天不到就接受了！只是修改语言, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73361629515, createdName=zhangsilin, createdTime=Sat Jun 10 00:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531311, encodeId=8e245313115e, content=一篇前年12月投稿到绿皮的手稿，历经一次中修和一次小修，最后接收并于去年年中发表。这篇文章最一开始投的是10+的杂志，经众一区杂志秒拒的洗礼，最后被绿皮接收，也算是一个不错的结果。谢谢编辑和审稿人的认可，尤其其中一位认为我们的工作是极具开创性的（a rather interesting new direction of thought in the field）。希望在放射肿瘤学的主流杂志上（红皮和绿皮，当然更高级的CR等）有更多国人的声音,也希望所在的研究组在以后的日子里会有更多的工作在红皮、绿皮等权威杂志上发表。祝大家好运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=285, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Mon Jan 02 10:17:00 CST 2017, time=2017-01-02, status=1, ipAttribution=)]

2017-12-14 1dd96cb3m86(暂无匿称)

审稿速度:2.0 | 投稿命中率:25.0
经验分享：投稿过3次.前两次都在一周内被拒.这次With editor 13天后Under review.希望能顺利发表.

217 0

[GetPortalCommentsPageByObjectIdResponse(id=558351, encodeId=e0ad5583519e, content=距5分就差一丢丢.不知最终版可否超越5分...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Tue Jun 26 21:49:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553324, encodeId=5d245533241f, content=Received at Editorial Office: 30-NOV-2017 Article revised: 18-FEB-2018 Article accepted for publication: 26-FEB-2018 Expected dispatch of proofs: 12-MAR-2018188****8186(暂无匿称) 2018-01-22 23:44:00 发表: under review 40天后.Under Editor Evaluation, beContent=188****8186(暂无匿称) 2018-01-22 23:44:00 发表: under review 40天后.Under Editor Evaluation, objectType=tool_impact_factor, channel=null, level=null, likeNumber=249, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553117, encodeId=69cf55311e21, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Nov 30, 2017 提交 Feb 28, 2018Completed - Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Wed Feb 28 20:07:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551849, encodeId=df48551849fd, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：under review 40天后.Under Editor Evaluation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Jan 22 23:44:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551707, encodeId=2ba4551e07ef, content=红皮都过五了，投稿应该越来越难。。。绿皮还在4分几徘徊。。。祈祷它可以过五吧，bless...分数和声誉完全不匹配啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Fri Jan 19 19:26:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549999, encodeId=961f5499994b, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿过3次.前两次都在一周内被拒.这次With editor 13天后Under review.希望能顺利发表., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Thu Dec 14 12:44:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548511, encodeId=91a454851135, content=一篇综述，列出审稿时间，供参考 Initial Date Submitted Aug 29, 2017 Submitted to Journal Aug 29, 2017 With Editor Aug 31, 2017 Under Review Sep 10, 2017 Under Review Sep 12, 2017 Under Editor Evaluation Oct 23, 2017 Decision in Process Oct 23, 2017, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=299, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a22794, createdName=119254319, createdTime=Tue Oct 24 09:06:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544079, encodeId=8d245440e9d4, content=徘徊不前,不过处于这个关口上的期刊,再往上冲已不易了,4分多,也算满意了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=wang_di98, createdTime=Sun Jul 16 19:01:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=537566, encodeId=afef53e566c1, content=什么类型文章？zhu1270 2012-09-04 发表:: 奇怪的很，我投了20天不到就接受了！只是修改语言zhu1270 2012-09-04 16:10:00 发表: 奇怪的很，我投了20天不到就接受了！只是修改语言, beContent=zhu1270 2012-09-04 发表:: 奇怪的很，我投了20天不到就接受了！只是修改语言, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73361629515, createdName=zhangsilin, createdTime=Sat Jun 10 00:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531311, encodeId=8e245313115e, content=一篇前年12月投稿到绿皮的手稿，历经一次中修和一次小修，最后接收并于去年年中发表。这篇文章最一开始投的是10+的杂志，经众一区杂志秒拒的洗礼，最后被绿皮接收，也算是一个不错的结果。谢谢编辑和审稿人的认可，尤其其中一位认为我们的工作是极具开创性的（a rather interesting new direction of thought in the field）。希望在放射肿瘤学的主流杂志上（红皮和绿皮，当然更高级的CR等）有更多国人的声音,也希望所在的研究组在以后的日子里会有更多的工作在红皮、绿皮等权威杂志上发表。祝大家好运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=285, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Mon Jan 02 10:17:00 CST 2017, time=2017-01-02, status=1, ipAttribution=)]

2017-10-24 119254319

一篇综述，列出审稿时间，供参考
Initial Date Submitted Aug 29, 2017
Submitted to Journal Aug 29, 2017
With Editor Aug 31, 2017
Under Review Sep 10, 2017
Under Review Sep 12, 2017
Under Editor Evaluation Oct 23, 2017
Decision in Process Oct 23, 2017

299 0

[GetPortalCommentsPageByObjectIdResponse(id=558351, encodeId=e0ad5583519e, content=距5分就差一丢丢.不知最终版可否超越5分...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Tue Jun 26 21:49:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553324, encodeId=5d245533241f, content=Received at Editorial Office: 30-NOV-2017 Article revised: 18-FEB-2018 Article accepted for publication: 26-FEB-2018 Expected dispatch of proofs: 12-MAR-2018188****8186(暂无匿称) 2018-01-22 23:44:00 发表: under review 40天后.Under Editor Evaluation, beContent=188****8186(暂无匿称) 2018-01-22 23:44:00 发表: under review 40天后.Under Editor Evaluation, objectType=tool_impact_factor, channel=null, level=null, likeNumber=249, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553117, encodeId=69cf55311e21, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Nov 30, 2017 提交 Feb 28, 2018Completed - Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Wed Feb 28 20:07:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551849, encodeId=df48551849fd, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：under review 40天后.Under Editor Evaluation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Jan 22 23:44:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551707, encodeId=2ba4551e07ef, content=红皮都过五了，投稿应该越来越难。。。绿皮还在4分几徘徊。。。祈祷它可以过五吧，bless...分数和声誉完全不匹配啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Fri Jan 19 19:26:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549999, encodeId=961f5499994b, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿过3次.前两次都在一周内被拒.这次With editor 13天后Under review.希望能顺利发表., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Thu Dec 14 12:44:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548511, encodeId=91a454851135, content=一篇综述，列出审稿时间，供参考 Initial Date Submitted Aug 29, 2017 Submitted to Journal Aug 29, 2017 With Editor Aug 31, 2017 Under Review Sep 10, 2017 Under Review Sep 12, 2017 Under Editor Evaluation Oct 23, 2017 Decision in Process Oct 23, 2017, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=299, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a22794, createdName=119254319, createdTime=Tue Oct 24 09:06:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544079, encodeId=8d245440e9d4, content=徘徊不前,不过处于这个关口上的期刊,再往上冲已不易了,4分多,也算满意了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=wang_di98, createdTime=Sun Jul 16 19:01:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=537566, encodeId=afef53e566c1, content=什么类型文章？zhu1270 2012-09-04 发表:: 奇怪的很，我投了20天不到就接受了！只是修改语言zhu1270 2012-09-04 16:10:00 发表: 奇怪的很，我投了20天不到就接受了！只是修改语言, beContent=zhu1270 2012-09-04 发表:: 奇怪的很，我投了20天不到就接受了！只是修改语言, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73361629515, createdName=zhangsilin, createdTime=Sat Jun 10 00:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531311, encodeId=8e245313115e, content=一篇前年12月投稿到绿皮的手稿，历经一次中修和一次小修，最后接收并于去年年中发表。这篇文章最一开始投的是10+的杂志，经众一区杂志秒拒的洗礼，最后被绿皮接收，也算是一个不错的结果。谢谢编辑和审稿人的认可，尤其其中一位认为我们的工作是极具开创性的（a rather interesting new direction of thought in the field）。希望在放射肿瘤学的主流杂志上（红皮和绿皮，当然更高级的CR等）有更多国人的声音,也希望所在的研究组在以后的日子里会有更多的工作在红皮、绿皮等权威杂志上发表。祝大家好运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=285, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Mon Jan 02 10:17:00 CST 2017, time=2017-01-02, status=1, ipAttribution=)]

2017-07-16 wang_di98

徘徊不前,不过处于这个关口上的期刊,再往上冲已不易了,4分多,也算满意了

311 0

[GetPortalCommentsPageByObjectIdResponse(id=558351, encodeId=e0ad5583519e, content=距5分就差一丢丢.不知最终版可否超越5分...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Tue Jun 26 21:49:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553324, encodeId=5d245533241f, content=Received at Editorial Office: 30-NOV-2017 Article revised: 18-FEB-2018 Article accepted for publication: 26-FEB-2018 Expected dispatch of proofs: 12-MAR-2018188****8186(暂无匿称) 2018-01-22 23:44:00 发表: under review 40天后.Under Editor Evaluation, beContent=188****8186(暂无匿称) 2018-01-22 23:44:00 发表: under review 40天后.Under Editor Evaluation, objectType=tool_impact_factor, channel=null, level=null, likeNumber=249, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553117, encodeId=69cf55311e21, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Nov 30, 2017 提交 Feb 28, 2018Completed - Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Wed Feb 28 20:07:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551849, encodeId=df48551849fd, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：under review 40天后.Under Editor Evaluation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Jan 22 23:44:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551707, encodeId=2ba4551e07ef, content=红皮都过五了，投稿应该越来越难。。。绿皮还在4分几徘徊。。。祈祷它可以过五吧，bless...分数和声誉完全不匹配啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Fri Jan 19 19:26:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549999, encodeId=961f5499994b, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿过3次.前两次都在一周内被拒.这次With editor 13天后Under review.希望能顺利发表., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Thu Dec 14 12:44:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548511, encodeId=91a454851135, content=一篇综述，列出审稿时间，供参考 Initial Date Submitted Aug 29, 2017 Submitted to Journal Aug 29, 2017 With Editor Aug 31, 2017 Under Review Sep 10, 2017 Under Review Sep 12, 2017 Under Editor Evaluation Oct 23, 2017 Decision in Process Oct 23, 2017, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=299, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a22794, createdName=119254319, createdTime=Tue Oct 24 09:06:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544079, encodeId=8d245440e9d4, content=徘徊不前,不过处于这个关口上的期刊,再往上冲已不易了,4分多,也算满意了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=wang_di98, createdTime=Sun Jul 16 19:01:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=537566, encodeId=afef53e566c1, content=什么类型文章？zhu1270 2012-09-04 发表:: 奇怪的很，我投了20天不到就接受了！只是修改语言zhu1270 2012-09-04 16:10:00 发表: 奇怪的很，我投了20天不到就接受了！只是修改语言, beContent=zhu1270 2012-09-04 发表:: 奇怪的很，我投了20天不到就接受了！只是修改语言, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73361629515, createdName=zhangsilin, createdTime=Sat Jun 10 00:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531311, encodeId=8e245313115e, content=一篇前年12月投稿到绿皮的手稿，历经一次中修和一次小修，最后接收并于去年年中发表。这篇文章最一开始投的是10+的杂志，经众一区杂志秒拒的洗礼，最后被绿皮接收，也算是一个不错的结果。谢谢编辑和审稿人的认可，尤其其中一位认为我们的工作是极具开创性的（a rather interesting new direction of thought in the field）。希望在放射肿瘤学的主流杂志上（红皮和绿皮，当然更高级的CR等）有更多国人的声音,也希望所在的研究组在以后的日子里会有更多的工作在红皮、绿皮等权威杂志上发表。祝大家好运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=285, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Mon Jan 02 10:17:00 CST 2017, time=2017-01-02, status=1, ipAttribution=)]

2017-06-10 zhangsilin

什么类型文章？zhu1270 2012-09-04 发表::
奇怪的很，我投了20天不到就接受了！只是修改语言zhu1270 2012-09-04 16:10:00 发表:
奇怪的很，我投了20天不到就接受了！只是修改语言

zhu1270 2012-09-04 发表:: 奇怪的很，我投了20天不到就接受了！只是修改语言

251 0

[GetPortalCommentsPageByObjectIdResponse(id=558351, encodeId=e0ad5583519e, content=距5分就差一丢丢.不知最终版可否超越5分...., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=200, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Tue Jun 26 21:49:00 CST 2018, time=2018-06-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553324, encodeId=5d245533241f, content=Received at Editorial Office: 30-NOV-2017 Article revised: 18-FEB-2018 Article accepted for publication: 26-FEB-2018 Expected dispatch of proofs: 12-MAR-2018188****8186(暂无匿称) 2018-01-22 23:44:00 发表: under review 40天后.Under Editor Evaluation, beContent=188****8186(暂无匿称) 2018-01-22 23:44:00 发表: under review 40天后.Under Editor Evaluation, objectType=tool_impact_factor, channel=null, level=null, likeNumber=249, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Tue Mar 06 00:00:00 CST 2018, time=2018-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=553117, encodeId=69cf55311e21, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：Nov 30, 2017 提交 Feb 28, 2018Completed - Accept, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=208, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Wed Feb 28 20:07:00 CST 2018, time=2018-02-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551849, encodeId=df48551849fd, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：under review 40天后.Under Editor Evaluation, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=246, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Mon Jan 22 23:44:00 CST 2018, time=2018-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=551707, encodeId=2ba4551e07ef, content=红皮都过五了，投稿应该越来越难。。。绿皮还在4分几徘徊。。。祈祷它可以过五吧，bless...分数和声誉完全不匹配啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Fri Jan 19 19:26:00 CST 2018, time=2018-01-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=549999, encodeId=961f5499994b, content=审稿速度:2.0 | 投稿命中率:25.0 经验分享：投稿过3次.前两次都在一周内被拒.这次With editor 13天后Under review.希望能顺利发表., beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=217, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Thu Dec 14 12:44:00 CST 2017, time=2017-12-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=548511, encodeId=91a454851135, content=一篇综述，列出审稿时间，供参考 Initial Date Submitted Aug 29, 2017 Submitted to Journal Aug 29, 2017 With Editor Aug 31, 2017 Under Review Sep 10, 2017 Under Review Sep 12, 2017 Under Editor Evaluation Oct 23, 2017 Decision in Process Oct 23, 2017, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=299, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2f5a22794, createdName=119254319, createdTime=Tue Oct 24 09:06:00 CST 2017, time=2017-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=544079, encodeId=8d245440e9d4, content=徘徊不前,不过处于这个关口上的期刊,再往上冲已不易了,4分多,也算满意了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=311, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=wang_di98, createdTime=Sun Jul 16 19:01:00 CST 2017, time=2017-07-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=537566, encodeId=afef53e566c1, content=什么类型文章？zhu1270 2012-09-04 发表:: 奇怪的很，我投了20天不到就接受了！只是修改语言zhu1270 2012-09-04 16:10:00 发表: 奇怪的很，我投了20天不到就接受了！只是修改语言, beContent=zhu1270 2012-09-04 发表:: 奇怪的很，我投了20天不到就接受了！只是修改语言, objectType=tool_impact_factor, channel=null, level=null, likeNumber=251, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=73361629515, createdName=zhangsilin, createdTime=Sat Jun 10 00:00:00 CST 2017, time=2017-06-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=531311, encodeId=8e245313115e, content=一篇前年12月投稿到绿皮的手稿，历经一次中修和一次小修，最后接收并于去年年中发表。这篇文章最一开始投的是10+的杂志，经众一区杂志秒拒的洗礼，最后被绿皮接收，也算是一个不错的结果。谢谢编辑和审稿人的认可，尤其其中一位认为我们的工作是极具开创性的（a rather interesting new direction of thought in the field）。希望在放射肿瘤学的主流杂志上（红皮和绿皮，当然更高级的CR等）有更多国人的声音,也希望所在的研究组在以后的日子里会有更多的工作在红皮、绿皮等权威杂志上发表。祝大家好运！, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=285, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210711/c1cc6c482d21459da935cfac488063b2/6e9e12c2bcaa465a9230f699381f6e1d.jpg, createdBy=f0911736061, createdName=@MD & PhD@, createdTime=Mon Jan 02 10:17:00 CST 2017, time=2017-01-02, status=1, ipAttribution=)]

2017-01-02 @MD & PhD@

一篇前年12月投稿到绿皮的手稿，历经一次中修和一次小修，最后接收并于去年年中发表。这篇文章最一开始投的是10+的杂志，经众一区杂志秒拒的洗礼，最后被绿皮接收，也算是一个不错的结果。谢谢编辑和审稿人的认可，尤其其中一位认为我们的工作是极具开创性的（a rather interesting new direction of thought in the field）。希望在放射肿瘤学的主流杂志上（红皮和绿皮，当然更高级的CR等）有更多国人的声音,也希望所在的研究组在以后的日子里会有更多的工作在红皮、绿皮等权威杂志上发表。祝大家好运！

285 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务